In a coverage launch on Monday, Malik has rated HARV a “Buy” with a C$19.00 target price, representing a 12-month projected return of 139.0 per cent at the time of publication.
Arizona-based multi-state operator Harvest Health is one of the largest MSOs in the US and on a proforma basis holds 142 retail licenses and 77 cultivation/processing licenses, with licenses and operations across 17 states. Along with Arizona, where Harvest has the largest market share, Malik sees other key states for the company being Florida, Pennsylvania, California, Nevada, Michigan, Maryland, Ohio, New Jersey and Illinois.
Malik says Harvest has developed a track record of growth through new license wins and acquisitions and he expects Harvest will have 94 retail locations open by the end of 2019 and 140 by the end of 2020. That’s along with production capacity of 130,000 pounds of cannabis (approx. 59,000 kg) and four million product units per year by the end of 2020.
“Harvest is one of the largest MSOs in the US and holds licenses in a number of attractive markets. We are forecasting strong growth as the Company operationalizes existing licenses, establishing one of the largest vertically integrated footprints of any MSO. Upcoming sales of CBD products provide additional growth potential,” says Malik.
The analyst says HARV is currently trading at a discount to its peer group, at 2.6x EV/Sales and 8.2x EV/EBITDA compared to the peer average of 3.7x and 12.0x, respectively. Malik thinks HARV will generate fiscal 2019 revenue and EBITDA of $325.7 million and $68.2 million, respectively, and fiscal 2020 revenue and EBITDA of $913.8 million and $286.3 million, respectively. (All figures in US dollars unless noted otherwise.)
RBC Dominion Securities analyst Paul Treiber raised his target on Shopify (Shopify Stock Quote, Chart, News, Analysts, Financials NYSE:SHOP) to… [Read More]
Newman Group senior wealth advisor and portfolio manager Greg Newman says Alphabet (Alphabet Stock Quote, Chart, News, Analysts, Financials NASDAQ:GOOGL)… [Read More]
Roth Capital Partners analyst Gerry Sweeney maintained his “Buy” rating and US$170.00 target on AZZ (AZZ Stock Quote, Chart, News,… [Read More]
Fintech stocks could be finding support from renewed investment after a difficult stretch for the sector, according to Dmytro Spilka.… [Read More]
Clean hydrogen technology and cellular concrete offer different investment opportunities, but analysts covering Syntholene Energy (Syntholene Energy Stock Quote, Chart,… [Read More]
Beacon Securities analyst Gabriel Leung reiterated his “Buy” rating and $3.00 target on Carrier Connect Data Solutions (Carrier Connect Data… [Read More]